Galectin Therapeutics Inc
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 cl… Read more
Galectin Therapeutics Inc (GALT) - Net Assets
Latest net assets as of September 2025: $-125.30 Million USD
Based on the latest financial reports, Galectin Therapeutics Inc (GALT) has net assets worth $-125.30 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($12.87 Million) and total liabilities ($138.17 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-125.30 Million |
| % of Total Assets | -973.98% |
| Annual Growth Rate | N/A |
| 5-Year Change | -526.03% |
| 10-Year Change | -511.49% |
| Growth Volatility | 671.54 |
Galectin Therapeutics Inc - Net Assets Trend (2000–2024)
This chart illustrates how Galectin Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Galectin Therapeutics Inc (2000–2024)
The table below shows the annual net assets of Galectin Therapeutics Inc from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-103.07 Million | -71.10% |
| 2023-12-31 | $-60.24 Million | -87.12% |
| 2022-12-31 | $-32.19 Million | -1330.66% |
| 2021-12-31 | $2.62 Million | -89.19% |
| 2020-12-31 | $24.19 Million | -46.94% |
| 2019-12-31 | $45.59 Million | +560.99% |
| 2018-12-31 | $6.90 Million | +478.21% |
| 2017-12-31 | $1.19 Million | -90.07% |
| 2016-12-31 | $12.02 Million | -52.03% |
| 2015-12-31 | $25.05 Million | -10.46% |
| 2014-12-31 | $27.97 Million | +240.03% |
| 2013-12-31 | $8.23 Million | +3.92% |
| 2012-12-31 | $7.92 Million | +80.05% |
| 2011-12-31 | $4.40 Million | +359.56% |
| 2010-12-31 | $-1.69 Million | +62.08% |
| 2009-12-31 | $-4.47 Million | -852.45% |
| 2008-12-31 | $-469.00K | +83.96% |
| 2007-12-31 | $-2.92 Million | -13190.91% |
| 2006-12-31 | $-22.00K | -100.61% |
| 2005-12-31 | $3.58 Million | -64.54% |
| 2004-12-31 | $10.11 Million | +32.54% |
| 2003-12-31 | $7.62 Million | +371.68% |
| 2002-12-31 | $1.62 Million | +32.94% |
| 2001-12-31 | $1.22 Million | +2331.69% |
| 2000-12-31 | $50.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Galectin Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 40138200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $62.00K | % |
| Other Components | $298.44 Million | % |
| Total Equity | $-103.07 Million | 100.00% |
Galectin Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Galectin Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Isabella Bank Corporation
OTCQX:ISBA
|
$144.13 Million |
|
Tracsis plc
PINK:TCIIF
|
$144.17 Million |
|
Ganesha Ecosphere Limited
NSE:GANECOS
|
$144.18 Million |
|
Voxel S.A.
WAR:VOX
|
$144.21 Million |
|
Nanjing Wondux Environmental Protection Technology Corp Ltd
SHG:688178
|
$144.06 Million |
|
Shanghai Serum Bio-Technology Co. Ltd. A
SHG:688163
|
$144.05 Million |
|
Aspo Oyj
HE:ASPO
|
$144.00 Million |
|
GULF MARINE SVCS LS -02
F:G0M
|
$143.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Galectin Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -60,241,000 to -103,070,000, a change of -42,829,000.
- Net loss of 47,047,000 reduced equity.
- Dividend payments of 91,000 reduced retained earnings.
- Share repurchases of 845,000 reduced equity.
- Other factors increased equity by 5,154,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-47.05 Million | -45.65% |
| Dividends Paid | $91.00K | -0.09% |
| Share Repurchases | $845.00K | -0.82% |
| Other Changes | $5.15 Million | +5.0% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Galectin Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-12-31 | $0.02 | $3.15 | x |
| 2001-12-31 | $0.54 | $3.15 | x |
| 2002-12-31 | $0.59 | $3.15 | x |
| 2003-12-31 | $2.14 | $3.15 | x |
| 2004-12-31 | $2.35 | $3.15 | x |
| 2005-12-31 | $0.79 | $3.15 | x |
| 2006-12-31 | $0.00 | $3.15 | x |
| 2007-12-31 | $-0.45 | $3.15 | x |
| 2008-12-31 | $-0.06 | $3.15 | x |
| 2009-12-31 | $-0.56 | $3.15 | x |
| 2010-12-31 | $-0.18 | $3.15 | x |
| 2011-12-31 | $0.37 | $3.15 | x |
| 2012-12-31 | $0.52 | $3.15 | x |
| 2013-12-31 | $0.49 | $3.15 | x |
| 2014-12-31 | $1.28 | $3.15 | x |
| 2015-12-31 | $1.04 | $3.15 | x |
| 2016-12-31 | $0.41 | $3.15 | x |
| 2017-12-31 | $0.03 | $3.15 | x |
| 2018-12-31 | $0.18 | $3.15 | x |
| 2019-12-31 | $0.87 | $3.15 | x |
| 2020-12-31 | $0.42 | $3.15 | x |
| 2021-12-31 | $0.04 | $3.15 | x |
| 2022-12-31 | $-0.54 | $3.15 | x |
| 2023-12-31 | $-1.00 | $3.15 | x |
| 2024-12-31 | $-1.65 | $3.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Galectin Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-197.57%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | -380.00% | 0.00% | 0.00x | 4.60x | $-195.00K |
| 2001 | -326.54% | 0.00% | 0.00x | 1.45x | $-4.09 Million |
| 2002 | -227.57% | 0.00% | 0.00x | 1.41x | $-3.84 Million |
| 2003 | -63.92% | 0.00% | 0.00x | 1.05x | $-5.64 Million |
| 2004 | -71.05% | 0.00% | 0.00x | 1.10x | $-8.19 Million |
| 2005 | -182.64% | 0.00% | 0.00x | 1.39x | $-6.90 Million |
| 2006 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.19 Million |
| 2007 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.14 Million |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.10 Million |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.02 Million |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.46 Million |
| 2011 | -248.24% | 0.00% | 0.00x | 1.50x | $-11.35 Million |
| 2012 | -122.21% | 0.00% | 0.00x | 1.21x | $-10.47 Million |
| 2013 | -146.93% | 0.00% | 0.00x | 1.30x | $-12.91 Million |
| 2014 | -56.44% | 0.00% | 0.00x | 1.06x | $-18.59 Million |
| 2015 | -79.95% | 0.00% | 0.00x | 1.05x | $-22.53 Million |
| 2016 | -178.41% | 0.00% | 0.00x | 1.31x | $-22.64 Million |
| 2017 | -1360.85% | 0.00% | 0.00x | 3.49x | $-16.35 Million |
| 2018 | -201.51% | 0.00% | 0.00x | 1.31x | $-14.59 Million |
| 2019 | -29.16% | 0.00% | 0.00x | 1.06x | $-17.85 Million |
| 2020 | -96.99% | 0.00% | 0.00x | 1.22x | $-25.88 Million |
| 2021 | -1166.93% | 0.00% | 0.00x | 15.99x | $-30.79 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-35.56 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-35.04 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-36.74 Million |
Industry Comparison
This section compares Galectin Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Galectin Therapeutics Inc (GALT) | $-125.30 Million | -380.00% | N/A | $144.10 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |